Q BioMed (QBIO) 10-Q 14 Apr 22 2022 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Feb. 28, 2022	Apr. 11, 2022
Document and Entity Information
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Feb. 28, 2022
Entity File Number	000-55535
Entity Registrant Name	Q BIOMED INC.
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	30-0967746
Entity Address, Address Line One	c/o Ortoli Rosenstadt LLP
Entity Address, Address Line Two	366 Madison Avenue
Entity Address, Address Line Three	3rd Floor
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10017
City Area Code	212
Local Phone Number	588-0022
Title of 12(b) Security	None
Trading Symbol	QBIO
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		31,427,428
Entity Central Index Key	0001596062
Current Fiscal Year End Date	--11-30
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Feb. 28, 2022	Nov. 30, 2021
Current assets:
Cash	$ 137,183	$ 344,009
Accounts receivable	27,708	80,097
Prepaid expenses and other current assets	36,035	35,374
Total current assets	200,926	459,480
Intangible assets, net	337,500	350,000
Total Assets	538,426	809,480
Current liabilities:
Accounts payable	1,804,650	1,345,319
Accrued expenses	1,041,653	954,309
Accrued expenses - related party	71,500	71,500
Accrued interest payable	104,111	70,677
Debt	3,346,245	3,053,037
Total current liabilities	6,368,159	5,494,842
Total Liabilities	6,368,159	5,494,842
Commitments and Contingencies (Note 6)
Stockholders' Deficit:
Preferred stock
Common stock, $0.001 par value; 250,000,000 shares authorized; 28,647,788 and 23,816,489 shares issued and outstanding as of November 30, 2021 and 2020, respectively	31,025	28,648
Additional paid-in capital	54,397,659	53,335,901
Accumulated deficit	(66,332,332)	(64,126,618)
Total Stockholders' Deficit	(5,829,733)	(4,685,362)
Total Liabilities and Stockholders' Deficit	538,426	809,480
Convertible Series A Preferred Stock
Stockholders' Deficit:
Preferred stock	2,160,181	2,161,195
Convertible Series B Preferred Stock
Stockholders' Deficit:
Preferred stock	$ 3,913,734	$ 3,915,512

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Feb. 28, 2022	Nov. 30, 2021
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	100,000,000	100,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	31,024,865	28,647,788
Common stock, shares outstanding	31,024,865	28,647,788
Convertible Series A Preferred Stock
Preferred stock, shares authorized	500,000	500,000
Preferred stock, issued	227,998	227,998
Preferred stock, outstanding	227,998	227,998
Convertible Series B Preferred Stock
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, issued	400,000	400,000
Preferred stock, outstanding	400,000	400,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended
	Feb. 28, 2022	Feb. 28, 2021
Condensed Consolidated Statements of Operations
Net Sales	$ 75,059
Cost of sales	73,945	$ 40,593
Gross income (loss)	1,114	(40,593)
Operating expenses:
General and administrative expenses	1,096,300	2,137,332
Research and development expenses	69,268	173,430
Total operating expenses	1,165,568	2,310,762
Loss from operations	(1,164,454)	(2,351,355)
Other (income) expenses:
Interest expense	414,377	50,125
Change in fair value of embedded derivatives	235,817	17,401
Loss on debt extinguishment	232,100	56,122
Settlement of registration liability	241,875	0
Total other expenses	1,124,169	123,648
Net loss	(2,288,623)	(2,475,003)
Accumulated dividend on convertible preferred stock	(122,808)	(136,393)
Net loss attributable to common stockholders	$ (2,411,431)	$ (2,611,396)
Net loss per share - basic	$ (0.08)	$ (0.11)
Net loss per share - diluted	$ (0.08)	$ (0.11)
Weighted average shares outstanding, basic	29,594,999	24,644,761
Weighted average shares outstanding, diluted	29,594,999	24,644,761

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Shareholders' Deficit - USD ($)	Preferred stockSeries A convertible preferred stock	Preferred stockSeries B convertible preferred stock	Common Stock	Additional Paid in CapitalAdoption of ASU 2020-06	Additional Paid in Capital	Accumulated DeficitAdoption of ASU 2020-06	Accumulated Deficit	Adoption of ASU 2020-06	Total
Beginning balance, Shares at Nov. 30, 2020	227,998	503,134	23,816,489
Beginning balance, Amount at Nov. 30, 2020	$ 2,161,980	$ 4,968,368	$ 23,816		$ 47,656,423		$ (55,886,068)		$ (1,075,481)
Issuance Of Common Stock For Cash			$ 100		99,900				100,000
Issuance of common stock for cash (in shares)			100,000
Accumulated dividend on preferred stock	44,586	91,807			(136,393)
Issuance common stock for dividend payment on preferred stock	$ (45,600)	(100,627)	$ 135		146,092
Issuance common stock for dividend payment on preferred stock (in shares)			135,394
Issuance of common stock to convert notes payable			$ 168		202,846				203,014
Issuance of common stock to convert notes payable (in shares)			167,780
Issuance Of Common Stock To Convert Series B Preferred Stock		$ (1,031,340)	$ 1,245		1,030,095
Issuance of common stock to convert Series B preferred stock (in shares)		(103,134)	1,245,089
Issuance Cost Related To Issuance Of Convertible Notes			$ 35		34,790				34,825
Issuance cost related to issuance of convertible notes (in shares)			35,000
Beneficial conversion feature related to convertible notes					65,217				65,217
Share based compensation for services, Amount			$ 503		1,360,591				1,361,094
Net loss							(2,475,003)		(2,475,003)
Ending balance, Shares at Feb. 28, 2021	227,998	400,000	26,002,728
Ending balance, Amount at Feb. 28, 2021	$ 2,160,966	$ 3,928,208	$ 26,002		50,459,561		(58,361,071)		(1,786,334)
Beginning balance, Shares at Nov. 30, 2021	227,998	400,000	28,647,788
Beginning balance, Amount at Nov. 30, 2021	$ 2,161,195	$ 3,915,512	$ 28,648		53,335,901		(64,126,618)		(4,685,362)
Cash proceeds from warrants modification					20,000				20,000
Issuance of common stock to convert accrued liabilities			$ 26		9,773				9,799
Issuance of common stock to convert accrued liabilities (in shares)			26,627
Accumulated dividend on preferred stock	44,586	78,222			(122,808)
Issuance common stock for dividend payment on preferred stock	$ (45,600)	$ (80,000)	$ 278		125,322
Issuance common stock for dividend payment on preferred stock (in shares)			277,877
Issuance of common stock and warrants for cash			$ 400		99,630				100,030
Issuance of common stock and warrants for cash (in shares)			400,000
Issuance of common stock to convert notes payable			$ 1,578		1,052,369				1,053,947
Issuance of common stock to convert notes payable (in shares)			1,577,648
Beneficial conversion feature related to convertible notes									0
Share based compensation for services, Amount			$ 95		151,420				151,515
Share based compensation related to warrants modification, Amount					17,019				17,019
Net loss							(2,288,623)		(2,288,623)
Ending balance, Shares at Feb. 28, 2022	227,998	400,000	31,024,865
Ending balance, Amount at Feb. 28, 2022	$ 2,160,181	$ 3,913,734	$ 31,025	$ (290,967)	$ 54,397,659	$ 82,909	$ (66,332,332)	$ (208,058)	$ (5,829,733)

Consolidated Statement of Cash

Consolidated Statement of Cash Flows - USD ($)	3 Months Ended
	Feb. 28, 2022	Feb. 28, 2021
Cash flows from operating activities:
Net loss	$ (2,288,623)	$ (2,475,003)
Adjustments to reconcile net loss to net cash used in operating activities
Share based compensation for services	151,515	1,361,094
Share based compensation related to warrants modification	17,019	0
Change in fair value of embedded conversion option	235,817	17,401
Accretion of debt discount	351,805	39,632
Amortization expense	12,500	12,500
Settlement of registration liability	241,875	0
Loss on debt extinguishment	232,100	56,122
Inventory write-off	0	33,093
Changes in operating assets and liabilities:
Accounts receivable	52,389	0
Prepaid expenses and other current assets	(661)	6,625
Inventory	0	(33,093)
Accounts payable and accrued expenses	583,974	201,880
Accrued interest payable	33,434	(37,272)
Net cash used in operating activities	(376,856)	(817,021)
Cash flows from financing activities:
Proceeds received from issuance of convertible notes, net	0	975,000
Proceeds received for issuance of common stock and warrants	100,030	100,000
Cash advances	50,000	0
Proceeds received for warrants modification	20,000	0
Net cash provided by financing activities	170,030	1,075,000
Net (decrease) increase in cash	(206,826)	257,979
Cash at beginning of the year	344,009	177,145
Cash at end of the year	137,183	435,124
Supplemental disclosures:
Cash paid for interest	0	0
Cash paid for income taxes	0	0
Supplemental disclosures for noncash investing and financing activities:
Issuance of common stock to convert notes payable and accrued interest	1,053,947	203,014
Issuance of common stock to convert Series B preferred stock	0	1,031,340
Accumulated dividend on convertible preferred stock	122,808	136,393
Issuance of common stock for dividend payment on preferred stock	125,600	146,226
Issuance of common stock to convert accrued liabilities	9,799	0
Adoption of ASU 2020-06	208,058
Beneficial conversion feature related to convertible notes	$ 0	$ 65,217

Organization of the Company and

Organization of the Company and Description of the Business	3 Months Ended
	Feb. 28, 2022
Organization of the Company and Description of the Business
Organization of the Company and Description of the Business	Note 1 - Organization of the Company and Description of the Business Q BioMed Inc. (“Q BioMed”), and its wholly owned subsidiaries Q BioMed Cayman SEZC and QBMG Q BioMed Germany UG (collectively, “the Company”), is a biomedical acceleration and development company focused on licensing, acquiring and providing strategic resources to life sciences and healthcare companies. Q BioMed intends to mitigate risk by acquiring multiple assets over time and across a broad spectrum of healthcare related products, companies and sectors. The Company intends to develop these assets to provide returns via organic growth, revenue production, out-licensing, sale or the spinoff of new public companies. The accompanying condensed consolidated financial statements include the accounts of the Company’s wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

Basis of Presentation and Going

Basis of Presentation and Going Concern	3 Months Ended
	Feb. 28, 2022
Basis of Presentation and Going Concern
Basis of Presentation and Going Concern	Note 2 - Basis of Presentation and Going Concern Basis of Presentation The accompanying interim period unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. These condensed consolidated financial statements are unaudited and should be read in conjunction with the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended November 30, 2021 that was filed with SEC on February 28, 2022. Certain disclosures included in the annual financial statements have been condensed or omitted from these financial statements as they are not required for interim financial statements under U.S. GAAP and the rules of the SEC. These unaudited condensed consolidated financial statements reflect all adjustments that are, in the opinion of management, necessary for a fair statement of the results for the interim periods presented. These adjustments are of a normal, recurring nature. Interim period operating results may not be indicative of the operating results for a full year. Going Concern The accompanying condensed consolidated financial statements are prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has and is expected to incur net losses and cash outflows from operations in pursuit of extracting value from its acquired intellectual property. These matters, amongst others, raise doubt about the Company’s ability to continue as a going concern. Management anticipates that the Company will have to raise additional funds and/or generate revenue from drug sales within twelve months to continue operations. Additional funding will be needed to implement the Company’s business plan that includes various expenses such as fulfilling our obligations under licensing agreements, legal, operational set-up, general and administrative, marketing, employee salaries and other related start-up expenses. Obtaining additional funding will be subject to a number of factors, including general market conditions, investor acceptance of our business plan and initial results from our business operations. These factors may impact the timing, amount, terms or conditions of additional financing available to us. If the Company is unable to raise sufficient funds, management will be forced to scale back the Company’s operations or cease its operations. Management has determined that there is substantial doubt about the Company’s ability to continue as a going concern within one year after the condensed consolidated financial statements are issued. The accompanying condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classification of liabilities that might result from this uncertainty. COVID 19 The impact of the worldwide spread of a novel strain of coronavirus (“COVID-19”) has been unprecedented and unpredictable, but based on the Company’s current assessment, the Company does not expect any material impact on its long-term strategic plans, operations and its liquidity due to the worldwide spread of COVID-19. However, the Company is continuing to assess the effect on its operations by monitoring the spread of COVID-19 and the actions implemented to combat the virus throughout the world and its assessment of the impact of COVID-19 may change. The Impact of Russian Military Action in Ukraine On February 24, 2022, Russian forces launched significant military action against Ukraine, which has resulted in conflict and disruption in the region. The Company is monitoring the conflict in Ukraine and any broader economic effects from the crisis. To date, the conflict between Russia and Ukraine has not had a material impact on the Company's business, financial condition, or result of operations. ​

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Feb. 28, 2022
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	Note 3 - Summary of Significant Accounting Policies The Company’s significant accounting policies are disclosed in the audited financial statements for the year ended November 30, 2021 included in the Company’s Form 10-K. Recent Accounting Standards In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40). This ASU reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. This ASU provides guidance for a modification or an exchange of a freestanding equity-classified written call option that is not within the scope of another Topic. It specifically addresses: (1) how an entity should treat a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange; (2) how an entity should measure the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange; and (3) how an entity should recognize the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange. This ASU will be effective for all entities for fiscal years beginning after December 15, 2021. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted, including adoption in an interim period. The adoption of ASU 2021-04 is not expected to have a material impact on our financial statements or disclosures. Recently Adopted Accounting Standards In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. This ASU is effective for annual reporting periods beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. This update permits the use of either the modified retrospective or fully retrospective method of transition. The Company elected to early adopt this guidance on December 1, 2021, on a modified retrospective basis. The adoption resulted in approximately $291,000 decrease in additional paid in capital from the derecognition of the bifurcated equity component, $208,000 increase in debt from the derecognition of the discount associated with the bifurcated equity component and $83,000 decrease to the opening balance of accumulated deficit.

Loss per share

Loss per share	3 Months Ended
	Feb. 28, 2022
Loss per share
Loss per share	Note 4 - Loss per share Basic net loss per share was calculated by dividing net loss by the weighted-average shares of common stock outstanding during the period. Diluted net loss per share was calculated by dividing net loss by the weighted-average shares of common stock outstanding during the period using the treasury stock method or the two-class method, whichever is more dilutive. The table below summarizes potentially dilutive securities that were not considered in the computation of diluted net loss per share because they would be anti-dilutive (amounts are rounded to nearest thousand). ​ ​ ​ ​ ​ ​ Potentially dilutive securities February 28, 2022 November 30, 2021 Series A convertible preferred stock ​ 2,280,000 ​ 2,280,000 Series B convertible preferred stock ​ 11,429,000 ​ 11,429,000 Common stock purchase warrants ​ 12,152,000 ​ 11,752,000 Stock Options ​ 4,450,000 ​ 4,450,000 Convertible Notes 4,659,000 4,898,000 Potentially dilutive securities 34,970,000 34,809,000 ​

Debt

Debt	3 Months Ended
	Feb. 28, 2022
Debt
Debt	Note 5 - Debt ​ The table below summarizes outstanding debt as of February 28, 2022 and November 30, 2021 (amounts are rounded to nearest thousand): ​ ​ ​ ​ ​ ​ ​ ​ ​ February 28, 2022 November 30, 2021 Convertible Notes Payable: ​ ​ ​ ​ ​ ​ Principal value of 2021 Debentures ​ $ 3,053,000 ​ $ 3,506,000 Fair value of bifurcated contingent put option ​ 941,000 ​ 867,000 Debt discount ​ (698,000) ​ (1,320,000) Convertible notes payable, net ​ ​ 3,296,000 ​ ​ 3,053,000 Cash advances ​ ​ 50,000 ​ ​ — Total debt ​ $ 3,346,000 ​ $ 3,053,000 ​ Convertible Notes Payable February Debenture On February 12, 2021, the Company issued a debenture for $0.5 million (the “February Debenture”) pursuant to a securities purchase agreement with an accredited investor dated February 12, 2021. The February Debenture may be converted at any time on or prior to maturity at the lower of $1.15 or 93% of the average of the four lowest daily VWAPs during the 10 consecutive trading days immediately preceding the conversion date, provided that as long as we are not in default under the 2020 Debenture, the conversion price may never be less than $1.00. The debenture has a maturity date of February 12, 2022, provided that in case of an event of default, the debenture may become at the holder’s election immediately due and payable. The debenture bears interest at the rate of 5.5% per annum, and on issuance, the Company paid to the holder a commitment fee equal to 2% of the amount of the debenture. On January 21, 2022, the Company issued 1,055,000 shares of common stock to convert $0.5 million of outstanding debt and interest. The conversion price was reduced to $0.50. The Company recognized a loss on debt extinguishment of approximately $0.2 million as a result of the reduction of conversion price for the three months ended February 28, 2022. July Debenture On July 26, 2021, the Company entered into a securities purchase agreement with an accredited investor, pursuant to which the Company sold a convertible debenture (the “July Debenture”) in the principal amount of $806,250 and a warrant to purchase up to 645,000 shares of common stock (the “Warrant”) for a total purchase price of $750,000. The July Debenture has a maturity date of April 26, 2022, provided that in case of an event of default, the debenture may become at the holder’s election immediately due and payable. The July Debenture carries an interest rate of 10% per annum, provided that any principal or interest which is not paid when due shall bear interest at the rate of 15% per annum from the due date until payment (the “Default Interest”). The Company may prepay the Debenture at 120% of the outstanding aggregate principal amount within the first 60 days of issuance and at 130% of the sum of the outstanding principal amount, the accrued and unpaid interest on the unpaid principal amount and any Default Interest from 61 to 180 days after issuance. The holder may convert the July Debenture in its sole discretion at any time on or prior to maturity at the lower of $1.00 or 85% of the average of the four (4) lowest VWAPs during the 20 Trading Days prior to the date of such calculation. On December 15, 2021, the Company and the holder entered into a Mutual Release Agreement pursuant to which the holder agreed to add the $241,875 to the outstanding principal balance of July Debenture, for no consideration received by the Company, in order to resolve a breach of certain registration provisions of the securities purchase agreement. On February 9, 2022, the Company issued 522,648 shares of common stock to convert $0.2 million of outstanding debt. September Debenture On September 29, 2021, the Company entered into a securities purchase agreement with an accredited investor (“Lender”), pursuant to which the Company sold a convertible debenture (the “September Debenture”) in the principal amount of $2,200,000 with twelve-months term. The September Debenture includes an original issue discount of $185,000 and $15,000 for the payment of the Lender’s legal fees and carries an interest rate of 6% per annum. The Company also incurred other issuance cost of $247,350. On October 26, 2021, the September Debenture maturity date was extended for additional 3 months. The Company may prepay the September Debenture at 105% of the outstanding aggregate principal amount plus accrued interest within the first 60 days of issuance, at 112% of the outstanding aggregate principal amount plus accrued interest from 61-120 days after issuance and at 124% of the outstanding aggregate principal amount plus accrued interest from 121-180 days after issuance. The Debenture may not be prepaid after 180 days. The Lender has the right to convert all or any amount of the outstanding aggregate principal amount at any time at a fixed conversion price of $1.00 per share. The conversion price after six months shall be fixed to $0.50 per share. However, in the event the Company’s Common Stock trades below $0.50 per share for more than ten (10) consecutive trading days, the Lender is entitled to convert all or any amount of the outstanding aggregate principal amount into shares of the Company’s Common Stock at a Conversion Price for each share of Common Stock equal to 85% of the average of the 4 lowest VWAP’s in the prior 20 trading days. The fair value of the contingent put option in all outstanding debentures with the feature are revalued as of February 28, 2022 and November 30, 2021 based on the following weighted average key inputs: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ February 28, 2022 November 30, 2021 ​ Strike price ​ $ 0.64 ​ $ 0.71 ​ Terms (years) ​ ​ 0.6 ​ ​ 0.8 ​ Volatility ​ $ 0.86 ​ $ 0.71 ​ Risk-free rate ​ ​ 0.7 % ​ 0.2 % Dividend yield ​ ​ 0 % ​ 0 % ​ The following table presents changes in Level 3 liabilities measured at fair value for the three months ended February 28, 2022. Both observable and unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category. Unrealized gains and losses associated with liabilities within the Level 3 category include changes in fair value that were attributable to both observable (e.g., changes in market interest rates) and unobservable (e.g., changes in unobservable long- dated volatilities) inputs (amounts are rounded to nearest thousand). ​ ​ ​ ​ ​ Balance – December 1, 2021 $ 867,000 Debt extinguishment ​ (162,000) Change in fair value ​ 236,000 Balance – February 28, 2022 ​ $ 941,000 ​ Interest expense ​ Interest expense, included in the accompanying Condensed Consolidated Statements of Operations, is comprised of the following for each period presented (amounts are rounded to nearest thousand): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the three months ended ​ February 28, 2022 February 28, 2021 Interest expense based on the coupon interest rate of the outstanding debt ​ $ 61,000 ​ $ 10,000 Accretion of debt discount ​ ​ 352,000 ​ ​ 40,000 Other ​ ​ 1,000 ​ ​ — Total interest expense ​ $ 414,000 ​ $ 50,000 ​ Cash Advances Cash advances include cash provided by vendors or shareholders that is subject to repayment on demand.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Feb. 28, 2022
Commitments and Contingencies
Commitments and Contingencies	Note 6 - Commitments and Contingencies Legal Periodically, the Company reviews the status of significant matters, if any exist, and assesses its potential financial exposure. If the potential loss from any claim or legal claim is considered probable and the amount can be estimated, the Company accrues a liability for the estimated loss. Legal proceedings are subject to uncertainties, and the outcomes are difficult to predict. Because of such uncertainties, accruals are based on the best information available at the time. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation. On March 31, 2022, the Company received a complaint filed in the Court of Common Pleas in Buck County, Pennsylvania claiming that the Company had failed to pay approximately $106,000 in fees for services provided under two master services agreements that the Company entered into with the plaintiff. Under those agreements, the plaintiff was to have provided services in connection with the promotion of the Company's Strontium-89 product. The Company is analyzing how to respond to this recently received complaint. Advisory Agreements The Company entered into customary consulting arrangements with various counterparties to provide consulting services, business development and investor relations services, pursuant to which the Company agreed to issue shares of common stock as services are received. Lease Agreement In December 2016, one of our subsidiaries entered into a lease agreement for its office space located in Cayman Islands for $30,000 per annum. The initial term of the agreement ended in December 2019, and the Company has renewed its office lease agreement for another three years with the same terms. This agreement does not identify a specific asset and does not convey the use of substantially all of the shared office capacity. As such, this agreement does not contain a lease under ASC 842. The Company recognizes monthly license payments as incurred over the term of the arrangement. Rent expense is classified within general and administrative expenses on a straight-line basis.

Related Party Transactions

Related Party Transactions	3 Months Ended
	Feb. 28, 2022
Related Party Transactions
Related Party Transactions	Note 7 - Related Party Transactions The Company entered into consulting agreements with certain management personnel and stockholders for consulting and legal services. Consulting and legal expenses resulting from such agreements were included within general and administrative expenses in the accompanying Condensed Consolidated Statements of Operations as follows (amounts are rounded to nearest thousand): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the three months ended ​ February 28, 2022 February 28, 2021 Consulting and legal expenses ​ $ 105,000 ​ $ 105,000 ​

Stockholders' Deficit

Stockholders' Deficit	3 Months Ended
	Feb. 28, 2022
Stockholders' Deficit
Stockholders' Deficit	Note 8 - Stockholders’ Deficit As of February 28, 2022 and November 30, 2021, the Company is authorized to issue up to 250,000,000 shares of its $0.001 par value common stock and up to 100,000,000 shares of its $0.001 par value preferred stock. Preferred Shares The original issue price and the liquidation value per share, as of February 28, 2022, of each class of preferred stock is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ Original Issue Price Liquidation Value ​ ​ Per Share ​ Per Share Series A Preferred Share ​ $ 10.00 ​ $ 10.20 Series B Preferred Share ​ $ 10.00 ​ $ 10.20 ​ During the three months ended February 28, 2022, the Company issued total 227,877 shares of common stock as dividend payment on Series A and Series B preferred stock. The Company had accumulated dividends payable on the Preferred Shares of approximately $0.1 million as of February 28, 2022. Common Shares On February 14, 2022, the Company entered into a series of securities purchase agreements for the sale of 400,000 units at a $0.25 per unit sales price. The Company raised $100,000 in cash. Each unit consisted of one common share and one warrant to purchase one share of common stock at an exercise price of $0.50 . The common warrants issued on February 22, 2022 have a fair value of $0.28 per share, see Note 9. During the three months ended February 28, 2022, the Company issued 1,577,648 shares of common stock to convert $0.7 million of outstanding debt and interest. During the three months ended February 28, 2022, the Company issued 26,627 shares of common stock to convert approximately $10,000 of accrued expenses. During the three months ended February 28, 2022, the Company issued an aggregate of 94,925 shares of the Company’s common stock to various vendors for advisory services, valued at approximately $43,000 based on the estimated fair market value of the stock on the date of grant and was recognized within general and administrative expenses in the accompanying Condensed Consolidated Statements of Operations.

Warrants and Options

Warrants and Options	3 Months Ended
	Feb. 28, 2022
Warrants and Options
Warrants and Options	Note 9 - Warrants and Options Summary of warrants The following represents a summary of all outstanding warrants to purchase the Company’s common stock, including warrants issued to vendors for services and warrants issued as part of the units sold in the private placements, at February 28, 2022 and December 1, 2021 and the changes during the period then ended (warrants amount and intrinsic value are rounded to nearest thousand): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Average ​ ​ ​ ​ ​ ​ ​ ​ ​ Remaining ​ ​ ​ ​ ​ ​ ​ Weighted Average ​ Contractual ​ ​ ​ ​ ​ Warrants ​ Exercise Price ​ Life (years) ​ Intrinsic Value Outstanding at November 30, 2021 11,752,000 ​ ​ 1.97 2.60 ​ $ — Issued 400,000 ​ ​ 0.50 2.98 ​ ​ — Forfeited/expired — ​ ​ — — ​ ​ — Outstanding at February 28, 2022 12,152,000 ​ $ 1.89 2.4 ​ $ — Exercisable at February 28, 2022 12,152,000 ​ $ 1.89 2.4 ​ $ — ​ Warrants issued on February 22, 2022 were all equity classified. The fair value of the warrants on grant date was based on the following key inputs: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ February 22, 2022 Strike price ​ $ 0.50 ​ Terms (years) ​ 3.0 ​ Volatility ​ 126 % Risk-free rate ​ 1.7 % Dividend yield ​ 0.0 % ​ Modification of Warrants On February 1, 2022, the Company modified an aggregated of 245,625 warrants (the “Warrants”) that were originally granted to certain investors and consultants. The exercise price of the Warrants was reduced to $0.65 per share and the maturity date of the Warrants were extended until August 1, 2024. The Company received $20,000 cash from one of the investors as consideration for this modification. The Company immediately recognized approximately $17,000 incremental stock-based compensation on February 1, 2022 based on the following weighted average assumptions: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ After Modification Before Modification ​ Strike price ​ $ 0.65 ​ $ 2.33 ​ Term (years) ​ 2.5 ​ 2.1 ​ Volatility ​ 135 % 127 % Risk-free rate ​ 1.0 % 1.0 % Dividend yield ​ 0.0 % 0.0 % ​ Options Issued for Services The following represents a summary of all outstanding options to purchase the Company’s common stock at February 28, 2022: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Average ​ ​ ​ ​ ​ ​ ​ Weighted Average ​ Remaining Contractual ​ ​ ​ ​ Options Exercise Price Life (years) Intrinsic Value Outstanding at November 30, 2021 4,450,000 ​ $ 1.13 4.0 ​ $ 1,000 Issued — ​ ​ — — ​ ​ — Outstanding at February 28, 2022 4,450,000 ​ $ 1.13 3.1 ​ $ — Exercisable at February 28, 2022 4,000,000 ​ $ 1.21 2.9 ​ $ — ​ Stock-based Compensation The Company recognized general and administrative expenses of approximately $0.2 million and $1.4 million as a result of the shares, outstanding warrants and options issued to consultants and employees during the three months ended February 28, 2022 and 2021, respectively. As of February 28, 2022, the estimated unrecognized stock-based compensation associate with these agreements is approximately $101,000 and will be fully recognized by November 30, 2022.

Subsequent Events

Subsequent Events	3 Months Ended
	Feb. 28, 2022
Subsequent Events
Subsequent Events	Note 10 - Subsequent Events On March 4, 2022, the Company issued total 402,563 shares of common stock as dividend payment on Series A and Series B On April 5, 2022, the Company modified an aggregated of 266,666 warrants (the “Warrants”) that were originally granted to certain investors on May 20, 2021. The exercise price of the Warrants was reduced from $1.25 per share to $0.65 per share.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Feb. 28, 2022
Summary of Significant Accounting Policies
Recent Accounting Standards	Recent Accounting Standards In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40). This ASU reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. This ASU provides guidance for a modification or an exchange of a freestanding equity-classified written call option that is not within the scope of another Topic. It specifically addresses: (1) how an entity should treat a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange; (2) how an entity should measure the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange; and (3) how an entity should recognize the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange. This ASU will be effective for all entities for fiscal years beginning after December 15, 2021. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted, including adoption in an interim period. The adoption of ASU 2021-04 is not expected to have a material impact on our financial statements or disclosures.
Recently Adopted Accounting Standards	Recently Adopted Accounting Standards In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. This ASU is effective for annual reporting periods beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. This update permits the use of either the modified retrospective or fully retrospective method of transition. The Company elected to early adopt this guidance on December 1, 2021, on a modified retrospective basis. The adoption resulted in approximately $291,000 decrease in additional paid in capital from the derecognition of the bifurcated equity component, $208,000 increase in debt from the derecognition of the discount associated with the bifurcated equity component and $83,000 decrease to the opening balance of accumulated deficit.

Loss per share (Tables)

Loss per share (Tables)	3 Months Ended
	Feb. 28, 2022
Loss per share
Schedule of potentially dilutive securities not considered in the computation of diluted net loss per share	summarizes potentially dilutive securities that were not considered in the computation of diluted net loss per share because they would be anti-dilutive (amounts are rounded to nearest thousand). ​ ​ ​ ​ ​ ​ Potentially dilutive securities February 28, 2022 November 30, 2021 Series A convertible preferred stock ​ 2,280,000 ​ 2,280,000 Series B convertible preferred stock ​ 11,429,000 ​ 11,429,000 Common stock purchase warrants ​ 12,152,000 ​ 11,752,000 Stock Options ​ 4,450,000 ​ 4,450,000 Convertible Notes 4,659,000 4,898,000 Potentially dilutive securities 34,970,000 34,809,000

Debt (Tables)

Debt (Tables)	3 Months Ended
	Feb. 28, 2022
Debt
Schedule of convertible notes payable	The table below summarizes outstanding debt as of February 28, 2022 and November 30, 2021 (amounts are rounded to nearest thousand): ​ ​ ​ ​ ​ ​ ​ ​ ​ February 28, 2022 November 30, 2021 Convertible Notes Payable: ​ ​ ​ ​ ​ ​ Principal value of 2021 Debentures ​ $ 3,053,000 ​ $ 3,506,000 Fair value of bifurcated contingent put option ​ 941,000 ​ 867,000 Debt discount ​ (698,000) ​ (1,320,000) Convertible notes payable, net ​ ​ 3,296,000 ​ ​ 3,053,000 Cash advances ​ ​ 50,000 ​ ​ — Total debt ​ $ 3,346,000 ​ $ 3,053,000
Schedule of discounted maximum redemption premium	The fair value of the contingent put option in all outstanding debentures with the feature are revalued as of February 28, 2022 and November 30, 2021 based on the following weighted average key inputs: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ February 28, 2022 November 30, 2021 ​ Strike price ​ $ 0.64 ​ $ 0.71 ​ Terms (years) ​ ​ 0.6 ​ ​ 0.8 ​ Volatility ​ $ 0.86 ​ $ 0.71 ​ Risk-free rate ​ ​ 0.7 % ​ 0.2 % Dividend yield ​ ​ 0 % ​ 0 %
Summary of table presenting changes in Level 3 liabilities measured at fair value	​ ​ ​ ​ ​ Balance – December 1, 2021 $ 867,000 Debt extinguishment ​ (162,000) Change in fair value ​ 236,000 Balance – February 28, 2022 ​ $ 941,000
Schedule of interest expense	Interest expense, included in the accompanying Condensed Consolidated Statements of Operations, is comprised of the following for each period presented (amounts are rounded to nearest thousand): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the three months ended ​ February 28, 2022 February 28, 2021 Interest expense based on the coupon interest rate of the outstanding debt ​ $ 61,000 ​ $ 10,000 Accretion of debt discount ​ ​ 352,000 ​ ​ 40,000 Other ​ ​ 1,000 ​ ​ — Total interest expense ​ $ 414,000 ​ $ 50,000

Related Party Transactions (Tab

Related Party Transactions (Tables)	3 Months Ended
	Feb. 28, 2022
Related Party Transactions
Schedule of general and administrative expenses	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the three months ended ​ February 28, 2022 February 28, 2021 Consulting and legal expenses ​ $ 105,000 ​ $ 105,000

Stockholders' Deficit (Tables)

Stockholders' Deficit (Tables)	3 Months Ended
	Feb. 28, 2022
Stockholders' Deficit
Schedule original issue price and the liquidation value per share for each class of preferred stock	The original issue price and the liquidation value per share, as of February 28, 2022, of each class of preferred stock is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ Original Issue Price Liquidation Value ​ ​ Per Share ​ Per Share Series A Preferred Share ​ $ 10.00 ​ $ 10.20 Series B Preferred Share ​ $ 10.00 ​ $ 10.20

Warrants and Options (Tables)

Warrants and Options (Tables)	3 Months Ended
	Feb. 28, 2022
Schedule of fair value outstanding warrants and options issued to non-employees for services	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ February 22, 2022 Strike price ​ $ 0.50 ​ Terms (years) ​ 3.0 ​ Volatility ​ 126 % Risk-free rate ​ 1.7 % Dividend yield ​ 0.0 % The Company immediately recognized approximately $17,000 incremental stock-based compensation on February 1, 2022 based on the following weighted average assumptions: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ After Modification Before Modification ​ Strike price ​ $ 0.65 ​ $ 2.33 ​ Term (years) ​ 2.5 ​ 2.1 ​ Volatility ​ 135 % 127 % Risk-free rate ​ 1.0 % 1.0 % Dividend yield ​ 0.0 % 0.0 %
Common stock purchase warrants
Summary of warrants	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Average ​ ​ ​ ​ ​ ​ ​ ​ ​ Remaining ​ ​ ​ ​ ​ ​ ​ Weighted Average ​ Contractual ​ ​ ​ ​ ​ Warrants ​ Exercise Price ​ Life (years) ​ Intrinsic Value Outstanding at November 30, 2021 11,752,000 ​ ​ 1.97 2.60 ​ $ — Issued 400,000 ​ ​ 0.50 2.98 ​ ​ — Forfeited/expired — ​ ​ — — ​ ​ — Outstanding at February 28, 2022 12,152,000 ​ $ 1.89 2.4 ​ $ — Exercisable at February 28, 2022 12,152,000 ​ $ 1.89 2.4 ​ $ —
Stock Options
Schedule of Options issued for services	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Average ​ ​ ​ ​ ​ ​ ​ Weighted Average ​ Remaining Contractual ​ ​ ​ ​ Options Exercise Price Life (years) Intrinsic Value Outstanding at November 30, 2021 4,450,000 ​ $ 1.13 4.0 ​ $ 1,000 Issued — ​ ​ — — ​ ​ — Outstanding at February 28, 2022 4,450,000 ​ $ 1.13 3.1 ​ $ — Exercisable at February 28, 2022 4,000,000 ​ $ 1.21 2.9 ​ $ —

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details)	3 Months Ended
	Feb. 28, 2022USD ($)
Summary of Significant Accounting Policies
Decrease in additional paid in capital	$ 291,000
Increase in debt from derecognition of discount associated with bifurcated equity component	208,000
Decrease to opening balance of accumulated deficit	$ 83,000

Loss per share (Details)

Loss per share (Details) - shares	3 Months Ended	12 Months Ended
	Feb. 28, 2022	Nov. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share
Potentially dilutive securities	34,970,000	34,809,000
Series A convertible preferred stock
Antidilutive Securities Excluded from Computation of Earnings Per Share
Potentially dilutive securities	2,280,000	2,280,000
Series B convertible preferred stock
Antidilutive Securities Excluded from Computation of Earnings Per Share
Potentially dilutive securities	11,429,000	11,429,000
Common stock purchase warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share
Potentially dilutive securities	12,152,000	11,752,000
Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share
Potentially dilutive securities	4,450,000	4,450,000
Convertible Notes
Antidilutive Securities Excluded from Computation of Earnings Per Share
Potentially dilutive securities	4,659,000	4,898,000

Debt (Details)

Debt (Details) - USD ($)	Feb. 28, 2022	Nov. 30, 2021
Convertible Notes Payable:
Convertible notes payable, net	$ 3,296,000	$ 3,053,000
Cash advances	50,000
Total debt	3,346,000	3,053,000
2021 Debentures
Convertible Notes Payable:
Principal value	3,053,000	3,506,000
Fair value of bifurcated contingent put option	941,000	867,000
Debt discount	$ (698,000)	$ (1,320,000)

Debt - Fair value measurement i

Debt - Fair value measurement inputs (Details)	Feb. 28, 2022$ / shares	Nov. 30, 2021
Strike price
Convertible Notes
Input	0.64	0.71
Terms (years)
Convertible Notes
Input	0.6	0.8
Volatility
Convertible Notes
Input	0.86	0.71
Risk-free rate
Convertible Notes
Input	0.7	0.2
Dividend yield
Convertible Notes
Input	0	0

Debt - Changes in Level 3 liabi

Debt - Changes in Level 3 liabilities measured at fair value (Details)	3 Months Ended
	Feb. 28, 2022USD ($)
Debt
Balance - December 1, 2021	$ 867,000
Debt extinguishment	(162,000)
Change in fair value	236,000
Balance - February 28, 2022	$ 941,000

Debt - Interest expense (Detail

Debt - Interest expense (Details) - USD ($)	3 Months Ended
	Feb. 28, 2022	Feb. 28, 2021
Debt
Interest expense based on the coupon interest rate of the outstanding debt	$ 61,000	$ 10,000
Accretion of debt discount	$ 352,000	$ 40,000
Other	1,000	—
Total interest expense	$ 414,000	$ 50,000

Debt - Additional Information (

Debt - Additional Information (Details)	Feb. 09, 2022USD ($)shares	Jan. 21, 2022USD ($)$ / sharesshares	Dec. 15, 2021USD ($)	Sep. 29, 2021USD ($)item$ / shares	Jul. 26, 2021USD ($)itemD$ / sharesshares	Feb. 12, 2021USD ($)itemD$ / shares	Feb. 28, 2022USD ($)	Feb. 28, 2021USD ($)
Debt Instruments [Line Items]
Conversion price | $ / shares		$ 0.50
Shares issued, conversion of debt | shares	522,648	1,055,000
Amount of debt converted	$ 0.2	$ 500,000
Loss on debt extinguishment							$ (232,100)	$ (56,122)
Increase in outstanding principal balance			$ 241,875
2021 Debentures
Debt Instruments [Line Items]
Issue Of Debentures, Amount					$ 806,250	$ 500,000
Conversion price | $ / shares				$ 1
Percentage of average of the four lowest daily VWAPs on basis of which conversion price is reduced				85.00%	85.00%	93.00%
Number of lowest daily VWAPs during the 10 consecutive trading days on basis of which conversion price is reduced | item				4	4	4
Number of consecutive trading days				10	20	10
Interest rate (as percent)				6.00%	10.00%	5.50%
Commitment fee (as percent)						2.00%
Number of warrants issued | shares					645,000
Total purchase price					$ 750,000
Default interest rate					15.00%
Percent of prepayment within first 60 days of issuance				105.00%	120.00%
Percent of prepayment from 61 to 180 days after issuance					130.00%
Percent of prepayment from 61-120 days after issuance				112.00%
Carrying value of convertible notes				$ 2,200,000
Maturity period (in months)				12 months
Original issue discount				$ 185,000
Issuance costs				$ 15,000			$ 247,350
Percent of prepayment from 121 to 180 days after issuance				124.00%
Conversion price after six months | $ / shares				$ 0.50
Number of prior trading days in conversion price | item				20
2021 Debentures | Maximum
Debt Instruments [Line Items]
Conversion price | $ / shares					$ 1	$ 1.15
2021 Debentures | Minimum
Debt Instruments [Line Items]
Conversion price | $ / shares						$ 1

Commitments and Contingencies (

Commitments and Contingencies (Details)	1 Months Ended
	Mar. 31, 2022USD ($)item	Dec. 31, 2016USD ($)
Loss Contingencies [Line Items]
Damages sought	$ 106,000
Number of master services agreements | item	2
Lease agreement
Loss Contingencies [Line Items]
Lease cost per annum		$ 30,000
Renewal term (in years)		3 years

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	3 Months Ended
	Feb. 28, 2022	Feb. 28, 2021
Related Party Transactions
Consulting and legal expenses	$ 105,000	$ 105,000

Stockholders' Deficit (Details)

Stockholders' Deficit (Details) - $ / shares	Feb. 09, 2022	Jan. 21, 2022	Feb. 28, 2022	Nov. 30, 2021
Stockholders' Deficit
Common stock, shares authorized			250,000,000	250,000,000
Common stock, par value			$ 0.001	$ 0.001
Preferred stock, par value			$ 0.001	$ 0.001
Number of preferred shares authorized			100,000,000	100,000,000
Shares issued, conversion of debt	522,648	1,055,000

Stockholders' Deficit - Preferr

Stockholders' Deficit - Preferred Shares (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended
	Feb. 28, 2022	Feb. 14, 2022
Original Issue Price Per Share		$ 0.25
Series A convertible preferred stock
Original Issue Price Per Share	$ 10
Liquidation Value Per Share	10.20
Series B convertible preferred stock
Original Issue Price Per Share	10
Liquidation Value Per Share	$ 10.20
Preferred stock
Accumulated dividend on preferred stock	$ 0.1
Common Stock
Issuance common stock for dividend payment on series A and series B preferred stock	227,877

Stockholders' Deficit - Common

Stockholders' Deficit - Common Shares (Details) - USD ($)	Feb. 14, 2022	Feb. 28, 2022	Feb. 28, 2021
Issuance of common stock and warrants for cash (in shares)	400,000
Original Issue Price Per Share	$ 0.25
Proceeds from sale of securities	$ 100,000	$ 100,030
Number of common stock shares in unit	1
Number of warrants issued per unit	1
Number of shares issuable per warrants	1
Exercise price	$ 0.50
Fair Value of Warrants Per Share	$ 0.28
Share based compensation for services, Amount		$ 151,515	$ 1,361,094
Common Stock
Issuance of common stock and warrants for cash (in shares)		400,000
Proceeds from sale of securities		$ 400
Shares issued for conversion		1,577,648	167,780
Outstanding debt and interest		$ 700,000
Share based compensation for services, Shares		94,925	502,976
Share based compensation for services, Amount		$ 95	$ 503
Shares issued upon conversion of accrued expenses		26,627
Value of shares issued upon conversion of accrued expenses		$ 10,000
Series B convertible preferred stock
Original Issue Price Per Share		$ 10
General and Administrative Expense
Share based compensation for services, Shares		94,925
Share based compensation for services, Amount		$ 43,000

Warrants and Options - Summary

Warrants and Options - Summary of warrants (Details) - Common stock purchase warrants - $ / shares	Feb. 28, 2022	Nov. 30, 2021
Warrants
Issued	400,000
Ending balance	12,152,000	11,752,000
Exercisable at February 28, 2022	12,152,000
Weighted Average Exercise Price
Issued	$ 0.50
Ending balance	$ 1.89	$ 1.97
Exercisable at February 28, 2022	1.89
Weighted Average Remaining Contractual Life (years)
Beginning balance		2 years 7 months 6 days
Issued	2 years 11 months 23 days
Forfeited/expired	0 years
Ending balance	2 years 4 months 24 days
Exercisable at February 28, 2022	2 years 4 months 24 days

Warrants and Options - Fair val

Warrants and Options - Fair value of warrants and Modification of warrants (Details) - Stock Options - $ / shares	Feb. 22, 2022	Feb. 01, 2022
Strike price	$ 0.50
Term (years)	3 years
Volatility	126.00%
Risk-free rate	1.70%
Dividend yield	0.00%
After Modification
Strike price		$ 0.65
Term (years)		2 years 6 months
Volatility		135.00%
Risk-free rate		1.00%
Dividend yield		0.00%
Before Modification
Strike price		$ 2.33
Term (years)		2 years 1 month 6 days
Volatility		127.00%
Risk-free rate		1.00%
Dividend yield		0.00%

Warrants and Options - Addition

Warrants and Options - Additional Information (Details) - USD ($)	Feb. 01, 2022	Feb. 28, 2022	Feb. 28, 2021	Feb. 14, 2022
Number of modified warrants	245,625
Share based compensation related to warrants modification, Amount		$ 17,019
Exercise price of warrant				$ 0.50
Incremental stock-based compensation	$ 17,000
General and administrative expenses		1,096,300	$ 2,137,332
Unrecognized stock-based compensation		101,000,000,000
After Modification
Exercise price of warrant	$ 0.65
Amount of consideration received		20,000
Options And Warrants [Member]
General and administrative expenses		$ 200,000	$ 1,400,000

Warrants and Options - Summar_2

Warrants and Options - Summary of outstanding options (Details) - Stock Options	Feb. 28, 2022$ / sharesshares	Nov. 30, 2021$ / sharesshares
Options
Ending balance | shares	4,450,000	4,450,000
Exercisable at February 28, 2022 | shares	4,000,000
Weighted Average Exercise Price
Ending balance	$ 1.13	$ 1.13
Exercisable at February 28, 2022	1.21
Weighted Average Remaining Contractual Life (years)
Beginning balance		4 years
Issued	0 years
Ending balance	3 years 1 month 6 days
Exercisable at February 28, 2022	2 years 10 months 24 days
Intrinsic Value
Beginning balance		$ 1,000

Subsequent Events New (Details)

Subsequent Events New (Details) - $ / shares	Mar. 04, 2022	Apr. 05, 2022	Feb. 14, 2022
Subsequent Event [Line Items]
Exercise price of warrant			$ 0.50
Subsequent Event
Subsequent Event [Line Items]
Number of warrants issued		266,666
Subsequent Event | Maximum
Subsequent Event [Line Items]
Exercise price of warrant		$ 1.25
Subsequent Event | Minimum
Subsequent Event [Line Items]
Exercise price of warrant		$ 0.65
Subsequent Event | Series A convertible preferred stock
Subsequent Event [Line Items]
Dividend payment on Series A and Series B preferred stock	402,563
Subsequent Event | Series B convertible preferred stock
Subsequent Event [Line Items]
Dividend payment on Series A and Series B preferred stock	402,563